Atopic dermatitis boasts a large and transformative pipeline, says analyst

28 July 2021

dermatology_rheumatology_injection_stock_large

The atopic dermatitis (AD) space will see a total transformation over the next decade due to intense clinical activity, says analyst.

According to analytics firm GlobalData, 64% of the pipeline consists of small molecular agents while the rest comprises biologics. Most of these are interleukin inhibitors hoping to follow in the footsteps of Dupixent (dupilumab), which is marketed by France’s Sanofi (Euronext: SAN) and Regeneron (Nasdaq: REGN) and generated 3.5 billion euros ($4.2 billion) sales in 2020, up 73% on 2019,

However, there are some novel drug classes adding flare to the AD pipeline, including sphingosine 1-phosphate receptor (S1PR) modulators and OX40 inhibitors. The latter classes will help diversify the pipeline and act as a catalyst for more innovation in the AD realm.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK